Insider Transactions in Q2 2024 at Inari Medical, Inc. (NARI)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
Rebecca Chambers Director |
SELL
Open market or private sale
|
Direct |
260
-2.61%
|
$11,700
$45.99 P/Share
|
|
Jun 17
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,000
-1.17%
|
$1,760,000
$44.59 P/Share
|
|
Jun 12
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.35%
|
$235,000
$47.6 P/Share
|
|
Jun 12
2024
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.61%
|
$0
$0.46 P/Share
|
|
May 28
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
60,000
-6.48%
|
$3,000,000
$50.13 P/Share
|
|
May 28
2024
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.64%
|
$150,000
$50.0 P/Share
|
|
May 20
2024
|
Rebecca Chambers Director |
SELL
Open market or private sale
|
Direct |
964
-8.84%
|
$43,380
$45.39 P/Share
|
|
May 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,000
-2.09%
|
$1,840,000
$46.75 P/Share
|
|
May 13
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-1.08%
|
$270,000
$45.59 P/Share
|
|
May 13
2024
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+3.1%
|
$0
$0.46 P/Share
|
|
May 01
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
38,549
-1.28%
|
$1,619,058
$42.76 P/Share
|
|
Apr 24
2024
|
Catherine M. Szyman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+15.54%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Robert Keith Warner Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+25.35%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Donald B Milder Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+1.57%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Jonathan D Root Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+0.76%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Cynthia L Lucchese Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+9.7%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Dana G Mead Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+27.01%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
William Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+0.41%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Rebecca Chambers Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+27.44%
|
$173,292
$42.41 P/Share
|
|
Apr 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
1,451
-0.14%
|
$58,040
$40.0 P/Share
|
|
Apr 12
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-3.2%
|
$240,000
$40.96 P/Share
|
|
Apr 12
2024
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+3.1%
|
$0
$0.46 P/Share
|
|
Apr 01
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,067
-0.28%
|
-
|
|
Apr 01
2024
|
Andrew Hykes President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,222
-0.22%
|
-
|
|
Apr 01
2024
|
William Hoffman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,063
-0.1%
|
-
|
|
Apr 01
2024
|
Thomas Tu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,119
-0.16%
|
-
|